Type I interferonopathies in pediatric rheumatology
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Defective regulation of type I interferon response is associated with severe inflammatory phenotypes and autoimmunity. Type I interferonopathies are a clinically heterogenic group of Mendelian diseases with a constitutive activation of this pathway that might present as atypical, severe, early onset rheumatic diseases. Skin vasculopathy with chilblains and livedo reticularis, interstitial lung disease, and panniculitis are common. Recent studies have implicated abnormal responses to nucleic acid stimuli or defective regulation of downstream effector molecules in disease pathogenesis. As observed for IL1-β and autoinflammatory diseases, knowledge of the defects responsible for type I interferonopathies will likely promote the development of targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923
Lee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.-A., de Silva, U., Bailey, S. L., Witte, T., Vyse, T. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2091 · Cited by 730 · cited 1×
“2–2 % in the adult SLE population [44–46] and have been linked to a particular form of SLE presenting with skin lesions of the extremities induced by cold exposure, called chilblains (CHBL1, OMIM610448) [47–49].”
BackgroundMycobacterial Disease and Impaired IFN-γ Immunity in Humans with Inherited ISG15 Deficiency
Bogunovic, D., Byun, M., Durfee, L. A., Abhyankar, A., Sanal, O., Mansouri, D., Salem, S., Radovanovic, I., Grant, A. V., Adimi, P., et al. (2012) · Science · doi:10.1126/science.1224026 · Cited by 572
Jeremiah, N., Neven, B., Gentili, M., Callebaut, I., Maschalidi, S., Stolzenberg, M.-C., Goudin, N., Frémond, M.-L., Nitschke, P., Molina, T. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci79100 · Cited by 562 · cited 2×
“Similarly, activating mutations of nucleic acid receptors IFIH1 [26–28] and RIG-I [29] cause autosomal dominant AGS and Singleton-Merten syndrome interferonopathies, while activating mutations of STING cause SAVI syndrome in the absence of chronic infectious triggers [30, 31].”
BackgroundHuman intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation
Zhang, X., Bogunovic, D., Payelle-Brogard, B., Francois-Newton, V., Speer, S. D., Yuan, C., Volpi, S., Li, Z., Sanal, O., Mansouri, D., et al. (2015) · Nature · doi:10.1038/nature13801 · Cited by 558
Self-citationSTING and the innate immune response to nucleic acids in the cytosol
Burdette, D. L., & Vance, R. E. (2013) · Nature Immunology · doi:10.1038/ni.2491 · Cited by 501 · cited 2×
“cGAMP binds and activates the STING protein, which, following activation, translocates from the endothelial reticulum (ER) to the ER-Golgi intermediate compartments (ERGIC) [6] where the signal is propagated through the phosphorylation of the TANK-binding kinase 1 (TBK1) and of a family of protein called IFN regulator…”
BackgroundRice, G., Newman, W. G., Dean, J., Patrick, T., Parmar, R., Flintoff, K., Robins, P., Harvey, S., Hollis, T., O’Hara, A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513443 · Cited by 410
The enemy within: endogenous retroelements and autoimmune disease
Volkman, H. E., & Stetson, D. B. (2014) · Nature Immunology · doi:10.1038/ni.2872 · Cited by 333
Complement deficiencies and systemic lupus erythematosus
Truedsson, L., Bengtsson, A. A., & Sturfelt, G. (2007) · Autoimmunity · doi:10.1080/08916930701510673 · Cited by 315 · cited 1×
“The pattern of inheritance is AR and kidney (membranous proliferative glomerulonephritis) as well as skin involvement are common [58], together with an increased susceptibility for pyogenic infections.”
Background
Cited by
Kinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
Papendorf, J. J., Ebstein, F., Alehashemi, S., Piotto, D. G. P., Kozlova, A., Terreri, M. T., Shcherbina, A., Rastegar, A., Rodrigues, M., Pereira, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190104 · Cited by 38
“A common pathological feature of CANDLE/PRAAS is the presence of a sterile type I interferon (IFN) gene signature with persistent expression of typical IFN-induced genes (ISGs) in peripheral blood (19, 20).”
BackgroundReappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Piscianz, E., Cuzzoni, E., Sharma, R., Tesser, A., Sapra, P., & Tommasini, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170911162331 · Cited by 15
Metadata
- Authors
- Volpi, S., Picco, P., Caorsi, R., Candotti, F., & Gattorno, M.
- Venue
- Pediatric Rheumatology
- Published
- 2016-06-04
- Volume
- 14
- Issue
- 1
- Pages
- 35-35
- ISSN
- 1546-0096 (ISSN-L)
- OpenAlex
- W2416747496
- Cited by
- 131
- References
- 10
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type I interferonopathies in pediatric rheumatology. https://app.cochat.ai/papers/10.1186/s12969-016-0094-4
- The paper
- Volpi, S., Picco, P., Caorsi, R., Candotti, F., & Gattorno, M. (2016). Type I interferonopathies in pediatric rheumatology. Pediatric Rheumatology. https://doi.org/10.1186/s12969-016-0094-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.